Abstract
We conducted a retrospective review of the infectious complications and outcomes over a 2-year follow-up period of adult patients who received a second allogeneic hematopoietic cell transplant (2nd allo-HCT) during a five-year period at two cancer centers in Michigan. Sixty patients, of whom 44 (73%) had acute leukemia or myelodysplastic syndrome, were studied. The majority (n = 37,62%) received a 2nd allo-HCT because of relapsed leukemia. Infection episodes after the 2nd allo-HCT totaled 112. Bacteria were identified in 76 episodes, the majority of which occurred pre-engraftment. The most common infecting organisms were Enterococcus species and Clostridioides difficile. Viral infections, predominantly cytomegalovirus, accounted for 59 infection episodes and occurred mostly in pre-engraftment and early post-engraftment periods. There were 16 proven/probable fungal infections, of which 9 were invasive aspergillosis or candidiasis. Mortality was 45% (n = 27) at one year and 65% (n = 39) at 2 years after transplant, and 16 deaths (41%) were due to infection. Of those 16 infection deaths, 8 were bacterial, 4 fungal, 2 both bacterial and fungal, and 2 viral. Failure to engraft neutrophils or platelets was significantly associated with decreased survival, p < 0.0001 and p < 0.001, respectively. Infections are common after a 2nd allo-HCT and are associated with a high mortality rate.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others
Data availability
There is no data bank or repository associated with this study
References
Barrett AJ, Battiwalla M. Relapse after allogeneic stem cell transplantation. Expert Rev Hematol. 2010;3:429–41.
Masouridi-Levrat S, Simonetta F, Chalandon Y. Immunological basis of bone marrow failure after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:362. https://doi.org/10.3389/fimmu.2016.00362.
Arfons LM, Tomblyn M, Rocha V, Lazarus HM. Second hematopoietic stem cell transplantation in myeloid malignancies. Curr Opin Hematol. 2009;16:112–23.
Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol. 2000;111:292–302.
Platzbecker U, Binder M, Schmid C, Rutt C, Ehninger G, Bornhäuser M. Second donation of hematopoietic stem cells from unrelated donors for patients with relapse or graft failure after allogeneic transplantation. Haematologica 2008;93:1276–8.
Berger M, Pessolano R, Carraro F, Saglio F, Vassallo EE, Fagioli F. Outcome of relapsed pediatric patients after second allogeneic hematopoetic stem cell transplantation: a retrospective study from a single institution. J Pediatr Hematol Oncol. 2019;41:e506–e509.
Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, et al. Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Exp Hematol Oncol. 2019;8:1. https://doi.org/10.1186/s40164-018-0125-6.
Shimoni A, Labopin M, Finke J, Ciceri F, Deconinck E, Kröger N, et al. Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. Blood Cancer J. 2019;9:88. https://doi.org/10.1038/s41408-019-0251-3.
Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:882–913.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.
Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367–76.
Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91.
Martín-Peña A, Aguilar-Guisado M, Espigado I, Parody R, Miguel Cisneros J. Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients. Clin Transpl. 2011;25:468–74.
Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7:11–17.
Ninin E, Milpied N, Moreau P, André-Richet B, Morineau N, Mahé B, et al. Longitudinal study of bacteria, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis. 2001;33:41–47.
Miceli MH, Churay T, Braun T, Kauffman CA, Couriel DR. Risk factors and outcomes of invasive fungal infections in allogeneic hematopoietic cell transplant recipients. Mycopathologia 2017;182:495–504.
Schuster MG, Cleveland AA, Dubberke ER, Kauffman CA, Avery RK, Husain S, et al. Infections in hematopoietic cell transplant recipients: results from the Organ Transplant Infection Project, a multicenter, prospective cohort study. Open Forum Infect Dis. 2017;4:ofx050. https://doi.org/10.1093/ofid/ofx050.
Gea-Banacloche J Risk and epidemiology of infections after hematopoietic stem cell transplantation. In: Ljungman P, Snydman D, Boeckh M (eds). Ljungman’s Transplant Infections. 4th edn. (Springer International Publishing, Switzerland, 2016) pp 81–99.
Hefazi M, Damlaj M, Alkhateeb HB, Partain DK, Patel R, Razonable RR, et al. Vancomycin-resistant Enterococcus colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. Transpl Infect Dis. 2016;18:913–20.
Papanicolaou GA, Ustun C, Young JH, Chen M, Kim S, Ahn KW, et al. Bloodstream infection due to vancomycin-resistant Enterococcus is associated with increased mortality after hematopoietic cell transplantation for acute leukemia and myelodysplastic syndrome: a multicenter, retrospective cohort study. Clin Infect Dis. 2019;69:1771–9.
Vydra J, Shanley RM, George I, Ustun C, Smith AR, Weisdorg DJ, et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:764–70.
Alonso CD, Treadway SB, Hanna DB, Huff CA, Neofytos D, Carrol KC, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54:1053–63.
Dubberke ER, Reske KA, Olsen MA, Bommarito K, Cleveland AA, Silveira FP, et al. Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients. Transpl Infect Dis. 2018;20:e12855. https://doi.org/10.1111/tid.12855.
Willems L, Porcher R, Lafaurie M, Casin I, Robin M, Xhaard A, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2012;18:1295–1301.
Piñana JL, Montesinos P, Martino R, Vazquez L, Rovira M, López J, et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol. 2014;93:299–307.
Avery RK, Silveira FP, Benedict K, Cleveland AA, Kauffman CA, Schuster MG, et al. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study. Transpl Infect Dis. 2018;20:e12877. https://doi.org/10.1111/tid.12877.
Erard V, Guthrie KA, Seo S, Smith J, Huang ML, Chien J, et al. Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices. Clin Infect Dis. 2015;61:31–39.
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N. Engl J Med. 2017;377:2433–44.
Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornhäuser M, Groth C, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370:1781–9.
Kontoyiannis DP, Marr KA, Park BJ, Anaissie EJ, Andes DR, Baddley JW, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;5:1091–100.
Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48:265–73.
Lamoth F, Chung SJ, Damonti L, Alexander BD. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin Infect Dis. 2017;64:1619–21.
Salmanton-García J, Koehler P, Kindo A, Falces-Romero I, García-Rodríguez J, Ráčil Z, et al. Needles in a haystack: extremely rare invasive fungal infections reported in FungiScope-Global Registry for Emerging Fungal Infections. J Infect. 2020;81:802–15.
D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transpl. 2020;26:e177–e182.
Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156–64.
Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019;186:767–76.
Author information
Authors and Affiliations
Contributions
SMM: data collection, manuscript writing. KAL: data collection, result interpretation, manuscript writing. CAK: result interpretation, manuscript writing. PM: data collection. JA: data collection. PC: study design, manuscript review. SR: data collection, manuscript review. MHM: study design, data analysis, result interpretation, manuscript review.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Maurer, S.M., Linder, K.A., Kauffman, C.A. et al. Infectious complications after second allogeneic hematopoietic cell transplant in adult patients with hematological malignancies. Bone Marrow Transplant 57, 1820–1826 (2022). https://doi.org/10.1038/s41409-022-01827-y
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41409-022-01827-y
This article is cited by
-
Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation
International Journal of Hematology (2025)